Part II: One Infusion. A Permanent Gene Edit. A Lifetime of LDL Lowering. The VERVE-102 NEJM Data, the Lilly Acquisition Thesis, and What It Means.

VERVE-102 just published Phase 1b data in NEJM. Single IV infusion. 88% PCSK9 reduction. 62% LDL-C reduction. 18-month durability. No serious adverse events in 35 patients.

But the core problem being solved is not efficacy. Statins work. PCSK9 inhibitors work. The problem: roughly half of patients prescribed lipid-lowering therapy stop taking it within a…